• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.

    4/22/24 4:31:56 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email
    DEFA14A 1 defa14a.htm DEFA14A DEFA14A

    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material Pursuant to § 240.14a-12
    Acumen Pharmaceuticals, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    oFee paid previously with preliminary materials
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    Your control number Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials or the Stockholders Meeting To Be Held On June 4, 2024 For Stockholders of record as of April 8, 2024 To order paper materials, use one of the following methods. Internet: www.investorelections.com/ABOS Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders Tuesday, June 4, 2024 11:00 AM Eastern Time Annual Meeting to be held live via the internet - please visit www.proxydocs.com/ABOS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/ABOS iew the proxy materials, VOTE, and obtain directions to attend the meeting, go to www.proxydocs.com/ABOS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 24, 2024. styleINA P.O. BOX 8016, CARY, NC 27512-9903 SEE REVERSE FOR FULL AGENDA Scan QR for digital voting


     
    PROPOSAL 1. To elect two Class III directors to the Board of Directors, each to hold office until the 2027 Annual Meeting of Stockholders. 1.01 Daniel O'Connell 1.02 Nathan Fountain, M.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. 3. To conduct any other business properly brought before the meeting or any adjournments, continuations, or postponements thereof. THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL 1, AND FOR PROPOSAL 2 Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders


     

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS

    DatePrice TargetRatingAnalyst
    6/17/2025$4.00Buy
    Citigroup
    7/26/2024$7.00Buy
    Citigroup
    12/12/2023$8.00Buy
    Deutsche Bank
    7/20/2023$9.00 → $14.00Buy
    BofA Securities
    5/18/2023$13.00Overweight
    Cantor Fitzgerald
    7/15/2022$15.00Buy
    BTIG Research
    6/30/2022$15.00Buy
    H.C. Wainwright
    1/21/2022$16.00 → $14.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $ABOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

    Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $4.00

    6/17/25 7:48:19 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

    Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $7.00

    7/26/24 7:19:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Acumen Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $8.00

    12/12/23 6:44:55 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

    NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new research at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstrated improved delivery of AβO-targeting monoclonal antibodies to the central nervous system, including sabirnetug (ACU193), through the blood-brain barrier using the transferrin receptor (TfR) pathway,

    12/2/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

    NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present new findings at the upcoming 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in San Diego. The presentations include Acumen's recruitment strategies for its Phase 2 ALTITUDE-AD study of sabirnetug, as well as a nonclinical Enhanced Brain Delivery (EBD™) study focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the

    11/18/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease

    NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease. The open-label extension provides all participants who completed the 18-month placebo-controlled portion of ALTITUDE-AD with the opportunity to receive sabirnetug at 35 mg/kg administered intravenously once every four

    11/17/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    SEC Filings

    View All

    SEC Form 144 filed by Acumen Pharmaceuticals Inc.

    144 - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    1/22/26 4:16:05 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Acumen Pharmaceuticals Inc.

    144 - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    1/22/26 4:14:30 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Acumen Pharmaceuticals Inc.

    144 - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    1/22/26 4:13:45 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    Leadership Updates

    Live Leadership Updates

    View All

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lucy Therapeutics Appoints Kim Drapkin as Board Chair

    Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

    10/15/24 8:00:00 AM ET
    $ABOS
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer & Corp Sec Meisner Derek M exercised 17,756 shares at a strike of $1.85 and sold $53,280 worth of shares (17,756 units at $3.00) (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    1/28/26 7:50:04 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer & Corp Sec Meisner Derek M sold $16,721 worth of shares (8,934 units at $1.87), decreasing direct ownership by 5% to 173,999 units (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    1/23/26 6:12:54 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Siemers Eric sold $5,833 worth of shares (3,226 units at $1.81), decreasing direct ownership by 1% to 255,371 units (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    1/23/26 6:12:03 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    Financials

    Live finance-specific insights

    View All

    Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

    Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026  Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developi

    11/12/25 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

    NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please registe

    11/5/25 4:00:00 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

    Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or

    8/12/25 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    2/14/24 8:32:42 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Acumen Pharmaceuticals Inc.

    SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    2/6/24 9:02:25 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

    1/24/24 4:22:26 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care